A canadian cannabis stock that stands above the rest is Aphria (APHA). Compared to its competitors, Canopy Growth (CGC) and Aurora Cannabis (ACB), APHA already has a track record of success. While CGC and ACB have been struggling to write down goodwill due to high-priced acquisitions, APHA has…
avoided pricey acquisitions and kept a healthy balance sheet and a substantial amount of cash.
APHA has a strong record of sales growth. Its five-year revenue growth average is 206.2%. This is due to its portfolio of brands such as Aphria, Broken Coast, Solei, RIFF, and Good Supply. In its last reported results, net cannabis revenue was up 81% from the prior quarter. This is due to robust volume growth. The cost per dried gram remained low at CAD 0.88. This led to increased profitability for the company. Its adjusted EBITDA was up 49% from the third quarter, to CAD $8.6 million. APHA is currently the only Canadian cannabis producer that generates positive EBITDA.
Unlike its competitors, which sell consumer packaged goods, APHA focuses on flower and vape products. The company also had an extensive international distribution business, which has primarily driven revenue. APHA has operations in ten countries outside Canada. The company’s German subsidiary, CC Pharma, which it acquired last year, has access to nearly 70% of pharmacies in Germany.
APHA is No. 1 in terms of net revenue across all Canadian cannabis companies and it should continue to be for the foreseeable future. The company is going after the cannabis derivatives market. Derivatives are products such as edibles, cannabis-infused beverages, concentrates, topicals, and vapes. These were made legal in Canada late last year. Previously, only dried flower and cannabis oil were legal. The derivatives market is potentially more lucrative as margins are better. APHA is already the leading derivatives provider in Ontario.
APHA also has one of the best…
Continue reading at STOCKNEWS.com
